

IPW

1629

PI3806USW



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Alvaro et al.

Serial No.: 10/089,964

Group Art Unit: 1624

File Date: May 8, 2002

Examiner: R. Raymond

For: Chemical Compounds

Director of the U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

☒ Copies of the references are enclosed: 1-38

☐ Copies of the references were submitted in parent application Serial No. _____ (37 CFR 1.98(d))

☐ A copy of the International Search Report which issued on International Application No. _____ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. ☒ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:

- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311, whichever occurs first.

☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.


In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



Lorie Ann Morgan
Registration No. 38,181

Date: *3 May 2004*
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-8222
Facsimile: (919) 483-7988

FORM PTO 1449 INFORMATION DISCLOSURE STATEMENT <div style="border: 1px solid black; border-radius: 50%; padding: 5px; display: inline-block; transform: rotate(-45deg); transform-origin: center;"> MAY 06 2004 U.S. PATENT & TRADEMARK OFFICE </div>				ATTORNEY DOCKET NO. PI3806USW		SERIAL NO. 10/089,964	
				APPLICANT: ALVARO, ET AL.			
				FILING DATE: May 8, 2002		GROUP 1624	

U.S. PATENT DOCUMENTS							
Examiner Initials	Serial	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1	5,710,169	Jan. 20, 1998	Russell et al.			
	2	5,998,444	Dec. 7, 1999	Russell et al.			
	3	6,147,083	Nov. 14, 2000	Russell et al.			
	4	5,028,610	July 2, 1991	Hirai et al.			
	5	6,197,772	March 6, 2001	Janssens et al.			
	6	6,521,621	Feb. 18, 2003	Janssens et al.			
	7	RE 37,886	Oct. 15, 2002	Janssens et al.			
	8	5,696,123	Dec. 9, 1997	Dollinger et al.			
	9	5,708,006	Jan. 13, 1998	Dollinger et al.			

Continue on page 2

FOREIGN PATENT DOCUMENTS							
Serial	Document Number	Publication Date	Country	Class	Subclass	Translation Yes No	
10	WO 95/00498	Jan. 5, 1995	WIPO				
11	WO 02/057233	July 25, 2002	WIPO				
12	WO 02/032867	Apr. 25, 2002	WIPO				
13	WO 98/01133	Jan. 15, 1998	WIPO				Abstract only
14	WO 96/03378	Feb. 8, 1996	WIPO				Abstract only
15	WO 04/033428	Apr. 22, 2004	WIPO				
16	WO 97/36593	Oct. 9, 1997	WIPO				
17	WO 98/20001	May 14, 1998	WIPO				
18	WO 92/16211	Oct. 1, 1992	WIPO				
19	WO 99/26921	June 3, 1999	WIPO				
20	WO 96/14844	May 23, 1996	WIPO				
21	WO 96/20173	July 4, 1996	WIPO				
22	EP 718287	Dec. 19, 1995	EUROPE				
23	WO 99/09985	Mar. 4, 1999	WIPO				
24	WO 97/36889	Oct. 9, 1997	WIPO				
25	WO 97/36888	Oct. 9, 1997	WIPO				
26	WO 97/36592	Oct. 9, 1997	WIPO				

Continue on page _____

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)		
Serial	Document	Description

Continue on page _____

EXAMINER	DATE CONSIDERED
-----------------	------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

